Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices

Co-developed with specialty providers, the solution reflects continued investment in workflow efficiency, data visibility and practice performance

Cencora Logo Standard Blue RGB
Cencora Logo Standard Blue RGB

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control.

Developed with input from customer advisory boards and specialty care providers, the updated platform combines redesigned physical infrastructure with software and interface enhancements. The enhanced solution – which will be deployed in phases across more than 20 practice sites – is designed to improve visibility into inventory and patient-specific medication needs and support more coordinated workflows from ordering and tracking through storage and administration.

“The way inventory moves through a practice has a direct impact on both operational performance and patient care,” said Lisa Smith, SVP and President of Specialty Distribution and Solutions at Cencora. “Working alongside pharmacy and clinical teams, we co-developed the next generation Nucleus to streamline their experience while strengthening the solutions and infrastructure that support their day-to-day decision-making.”

Key features of the enhanced Nucleus solution include:

  • A modular cabinet design configured to support different workflows and practice needs;
  • A larger integrated touchscreen to improve visibility into patient and inventory data;
  • Built-in workspace enhancements that streamline the handling of physical inventory; and
  • A more unified interface designed to reduce complexity, shorten training time and improve consistency for clinical and administrative teams.

These enhancements build on Nucleus’ core functionality, which includes real-time inventory tracking, demand forecasting, automated billing support and access to a robust set of reporting tools that help practices manage cost, utilization and performance.

“As specialty therapies continue to evolve at a rapid pace, clinical care teams are managing increasing levels of complexity across clinical, financial and operational workflows,” said Camilo Rodriguez, Director of Pharmacy Operations at American Oncology Network and Cencora Advisory Board member. “By enhancing the infrastructure that supports inventory management, Cencora continues to collaboratively address providers’ unmet needs. The enhancements to Nucleus are designed to help practices operate more efficiently and maintain focus on delivering high-quality patient care.”

The pilot program will allow Cencora to evaluate system performance across a range of practice settings and gather feedback to inform broader deployment. Pending pilot outcomes, Cencora expects to begin scaling production and installation later this year, with expanded availability planned for existing and new customers.

To learn more about Cencora’s inventory management solutions, please visit the website here.

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #17 on the Global Fortune 500 with more than $300 billion in annual revenue.

Contacts

Michelle Engro

[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.